Immunization with Recombinant Sao Protein Confers Protection against Streptococcus suis Infection
Open Access
- 1 August 2007
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (8), 937-943
- https://doi.org/10.1128/cvi.00046-07
Abstract
Sao is a Streptococcus suis surface protein recently identified as a potential vaccine candidate. In this study, recombinant Sao in combination with Quil A provided cross-protection against S. suis serotype 2 disease in mouse and pig vaccination protocols. Subcutaneous immunization of mice elicited strong immunoglobulin G (IgG) antibody responses. All four IgG subclasses were induced, with the IgG2a titer being the highest, followed by those of IgG1, IgG2b, and IgG3. Challenge of the mice with S. suis strain 31533 resulted in a mortality rate of 80% for the control group, which received Quil A only. In contrast, all of the mice immunized with Sao survived. In a pig vaccination protocol, intramuscular immunization with Sao also elicited significant humoral antibody responses, and both the IgG1 and IgG2 subclasses were induced, with a predominance of IgG2 production. In vitro assay showed that Sao-induced antibodies significantly promoted the ability of porcine neutrophils in opsonophagocytic killing of S. suis. An aerosol challenge of the pigs with S. suis strain 166 resulted in clinical signs characteristic of S. suis infection in diseased pigs. The vaccine group showed significantly better survival, lower clinical scores, and less S. suis recovery from postmortem tissue samples than did the control group. Furthermore, this study also revealed that although challenge S. suis strains express Sao size variants, recombinant Sao conferred cross-protection. These data demonstrate that recombinant Sao formulated with Quil A triggers strong opsonizing antibody responses which confer efficient immunity against challenge infection with heterologous S. suis type 2.Keywords
This publication has 63 references indexed in Scilit:
- Identification of a Surface Protein of Streptococcus suis and Evaluation of Its Immunogenic and Protective Capacity in PigsInfection and Immunity, 2006
- Both Innate Immunity and Type 1 Humoral Immunity toStreptococcus pneumoniaeAre Mediated by MyD88 but Differ in Their Relative Levels of Dependence on Toll-Like Receptor 2Infection and Immunity, 2005
- Increased Protection against Pneumococcal Disease by Mucosal Administration of Conjugate Vaccine plus Interleukin-12Infection and Immunity, 2003
- Intranasal Vaccination with Pneumococcal Surface Protein A and Interleukin-12 Augments Antibody-Mediated Opsonization and Protective Immunity againstStreptococcus pneumoniaeInfectionInfection and Immunity, 2001
- INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative ApproachesAnnual Review of Immunology, 1997
- Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccinesVaccine, 1994
- Regulation of antibody isotype secretion by subsets of antigen-specific helper T cellsNature, 1988
- Structure and Function of Human and Murine Receptors for IgGAnnual Review of Immunology, 1988
- Activation of mouse complement by monoclonal mouse antibodiesEuropean Journal of Immunology, 1981
- Streptococcal infection in young pigs. V. An immunogenic polysaccharide from Streptococcus suis type 2 with particular reference to vaccination against streptococcal meningitis in pigsEpidemiology and Infection, 1980